The Antidote: Inside the World of New Pharma Author: Barry Werth | Language: English | ISBN:
B00DPM7ZW6 | Format: EPUB
The Antidote: Inside the World of New Pharma Description
IN
THE ANTIDOTE, Barry Werth draws upon unprecedented inside reporting spanning more than two decades to provide a groundbreaking closeup of the upstart pharmaceutical company Vertex and the ferocious but indispensable world of Big Pharma that it inhabits.
In 1989, the charismatic Joshua Boger left Merck, then America’s most admired business, to found a drug company that would challenge industry giants and transform health care. Werth described the company’s tumultuous early days during the AIDS crisis in
The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex’s bold endurance and eventual success.
The $325 billion-a-year pharmaceutical business is America’s toughest and one of its most profitable. It’s riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all the hurdles to get to human testing; to the multibillion-dollar cost of ramping up a successful product; to operating in the world’s most regulated industry, matched only by nuclear power.
Werth captures the full scope of Vertex’s twentyfive- year drive to deliver breakthrough medicines. At a time when America struggles to maintain its innovative edge,
The Antidote is a powerful inside look at one of the most intriguing and important business stories of recent decades.
- File Size: 4154 KB
- Print Length: 449 pages
- Page Numbers Source ISBN: 1451655665
- Publisher: Simon & Schuster (February 4, 2014)
- Sold by: Simon and Schuster Digital Sales Inc
- Language: English
- ASIN: B00DPM7ZW6
- Text-to-Speech: Not enabled
X-Ray:
- Lending: Not Enabled
- Amazon Best Sellers Rank: #27,623 Paid in Kindle Store (See Top 100 Paid in Kindle Store)
- #2
in Books > Medical Books > Pharmacology > Product Development - #3
in Kindle Store > Kindle eBooks > Nonfiction > Professional & Technical > Professional Science > Biological Sciences > Biotechnology - #3
in Kindle Store > Kindle eBooks > Nonfiction > Science > Biological Sciences > Biotechnology
- #2
in Books > Medical Books > Pharmacology > Product Development - #3
in Kindle Store > Kindle eBooks > Nonfiction > Professional & Technical > Professional Science > Biological Sciences > Biotechnology - #3
in Kindle Store > Kindle eBooks > Nonfiction > Science > Biological Sciences > Biotechnology
As a biomedical scientist I really enjoyed this book. It is the sequel to the author's previous volume "The Billion Dollar Molecule". Both books provide a fly-on-the-wall account of Vertex Pharmaceuticals, an innovative biopharmaceutical company that brought two breakthrough medicines - one for hepatitis C and the other for cystic fibrosis - to market two years ago. Both these drugs were the first of their kind and have given thousands of patients a new lease on life. From a broader perspective however, the author's goal is to shed light both on the immensely challenging process of bringing a new drug to market and the brilliant scientists and driven personalities that make it possible.
Werth's account of Vertex focuses mainly on the hepatitis C drug, with the cystic fibrosis drug playing a smaller but still important role. The previous book was much more science-heavy than this one, emphasizing the chemistry, biology and computer science that goes into the early stages of drug discovery. In spite of the intense scientific competition and research depicted in that volume (much of it spanning the late 80s and early 90s), Vertex did not bring a successful drug to market until 2010, underscoring the challenge of drug discovery in which you have to furiously paddle simply to stay afloat. The two books thus mirror two different phases of the company: the first dealing mainly with the science and the birthing pains of a new startup, and the second dealing with the transformation of the startup into a commercial enterprise. You will thus find much more of the business, legal and commercial aspects of drug development in this volume. Boardroom deliberations and the subtleties of drug pricing litter the narrative.
The Antidote: Inside the World of New Pharma Preview
Link
Please Wait...